Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases.
Hasseli R, Richter JG, Hoyer BF, Lorenz HM, Pfeil A, Regierer AC, Schmeiser T, Strangfeld A, Voll RE, Krause A, Reckert S, Gräßler A, Saar P, Kapelle A, Backhaus M, Blank N, Henes J, Osiek S, Knothe A, Hoese G, Brandt-Jürgens J, Maltzahn A, Specker C, Müller-Ladner U, Schulze-Koops H; COVID-19 task force of the German Society of Rheumatology collaborators; COVID19-Rheuma.de collaborators. Hasseli R, et al. RMD Open. 2023 Apr;9(2):e002998. doi: 10.1136/rmdopen-2023-002998. RMD Open. 2023. PMID: 37068915 Free PMC article.
National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD.
Hasseli R, Mueller-Ladner U, Schmeiser T, Hoyer BF, Krause A, Lorenz HM, Regierer AC, Richter JG, Strangfeld A, Voll RE, Pfeil A, Schulze-Koops H, Specker C. Hasseli R, et al. RMD Open. 2020 Sep;6(2):e001332. doi: 10.1136/rmdopen-2020-001332. RMD Open. 2020. PMID: 32878994 Free PMC article.
Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases.
Hasseli R, Mueller-Ladner U, Hoyer BF, Krause A, Lorenz HM, Pfeil A, Richter J, Schäfer M, Schmeiser T, Strangfeld A, Schulze-Koops H, Voll RE, Specker C, Regierer AC. Hasseli R, et al. RMD Open. 2021 Jan;7(1):e001464. doi: 10.1136/rmdopen-2020-001464. RMD Open. 2021. PMID: 33479021 Free PMC article.
[German registry www.Covid19-Rheuma.de : Status report after 1 year of the pandemic].
Hasseli R, Pfeil A, Hoyer BF, Lorenz HM, Regierer AC, Richter JG, Schmeiser T, Strangfeld A, Voll RE, Krause A, Schulze-Koops H, Müller-Ladner U, Specker C. Hasseli R, et al. Z Rheumatol. 2021 Sep;80(7):641-646. doi: 10.1007/s00393-021-01034-y. Epub 2021 Jul 1. Z Rheumatol. 2021. PMID: 34196793 Free PMC article. German.
Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic, including recommendations for COVID-19 vaccination.
Specker C, Aries P, Braun J, Burmester G, Fischer-Betz R, Hasseli R, Holle J, Hoyer BF, Iking-Konert C, Krause A, Krüger K, Krusche M, Leipe J, Lorenz HM, Moosig F, Schmale-Grede R, Schneider M, Strangfeld A, Voll R, Voormann A, Wagner U, Schulze-Koops H. Specker C, et al. Among authors: hasseli r. Z Rheumatol. 2021 Dec;80(Suppl 2):33-48. doi: 10.1007/s00393-021-01055-7. Epub 2021 Sep 7. Z Rheumatol. 2021. PMID: 34491403 Free PMC article. Review. No abstract available.
TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD.
Regierer AC, Hasseli R, Schäfer M, Hoyer BF, Krause A, Lorenz HM, Pfeil A, Richter J, Schmeiser T, Schulze-Koops H, Strangfeld A, Voll RE, Specker C, Mueller-Ladner U. Regierer AC, et al. Among authors: hasseli r. RMD Open. 2021 Oct;7(3):e001896. doi: 10.1136/rmdopen-2021-001896. RMD Open. 2021. PMID: 34670840 Free PMC article.
The influence of the SARS-CoV-2 lockdown on patients with inflammatory rheumatic diseases on their adherence to immunomodulatory medication: a cross sectional study over 3 months in Germany.
Hasseli R, Müller-Ladner U, Keil F, Broll M, Dormann A, Fräbel C, Hermann W, Heinmüller CJ, Hoyer BF, Löffler F, Özden F, Pfeiffer U, Saech J, Schneidereit T, Schlesinger A, Schwarting A, Specker C, Stapfer G, Steinmüller M, Storck-Müller K, Strunk J, Thiele A, Triantafyllias K, Vagedes D, Wassenberg S, Wilden E, Zeglam S, Schmeiser T. Hasseli R, et al. Rheumatology (Oxford). 2021 Oct 9;60(SI):SI51-SI58. doi: 10.1093/rheumatology/keab230. Rheumatology (Oxford). 2021. PMID: 33704418 Free PMC article.
43 results